Mitotic inhibitors

From WikiMD's Medical Encyclopedia

Revision as of 03:20, 2 April 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Mitotic inhibitors are a class of drugs that disrupt the process of mitosis in cell division. These agents interfere with the microtubules structures in the cell, which are essential for chromosome separation during the M phase of the cell cycle. By inhibiting mitosis, these drugs can halt the proliferation of cancer cells, making them a key component in the treatment of various cancers.

Mechanism of Action[edit]

Mitotic inhibitors work by targeting the microtubules, which are dynamic structures composed of tubulin proteins. These microtubules form the mitotic spindle, essential for chromosome alignment and separation during mitosis. There are two main classes of mitotic inhibitors based on their mechanism of action:

1. Microtubule-stabilizing agents: These drugs, such as paclitaxel and docetaxel, bind to tubulin and stabilize microtubules, preventing their disassembly. This stabilization halts the cell in the metaphase of mitosis, leading to cell death.

2. Microtubule-destabilizing agents: Agents like vincristine and vinblastine bind to tubulin and inhibit its polymerization into microtubules. This action disrupts the formation of the mitotic spindle, preventing the cell from successfully completing mitosis.

Clinical Use[edit]

Mitotic inhibitors are primarily used in the treatment of cancer. By preventing the proliferation of cancer cells, these drugs can reduce tumor growth and spread. They are used in various chemotherapy regimens, often in combination with other drugs, to treat a wide range of cancers, including breast cancer, lung cancer, ovarian cancer, and lymphoma.

Side Effects[edit]

The use of mitotic inhibitors is associated with several side effects, due to their effect on rapidly dividing cells, which are not limited to cancer cells. Common side effects include:

  • Neutropenia - a decrease in neutrophils, a type of white blood cell, leading to increased risk of infection
  • Anemia - a decrease in red blood cells, causing fatigue and weakness
  • Thrombocytopenia - a decrease in platelets, leading to increased risk of bleeding
  • Peripheral neuropathy - damage to the peripheral nerves, causing pain, numbness, and tingling in the hands and feet
  • Alopecia - hair loss

Future Directions[edit]

Research is ongoing to develop new mitotic inhibitors with greater efficacy and fewer side effects. This includes the identification of novel targets within the mitotic process and the development of drugs that are more selective for cancer cells. Additionally, efforts are being made to understand mechanisms of resistance to mitotic inhibitors, with the aim of developing strategies to overcome this challenge.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.